Health Studies MN

Within 


Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

3289 Study Matches

Sorting by: Relevance Distance

A ProspecTive Prevalence Study in Adolescent and Adult Patients Dependent on Parenteral Nutrition to Assess tHe Incidence of Intestinal FailuRe-AssocIated LiVer DiseasE (THRIVE-1)

Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition (THRIVE-1)

Manpreet Mundi
All
12 years to 80 years old
This study is NOT accepting healthy volunteers
2021-305761-P01-RST
21-009120
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


- The participant and/or their parent/Legally Authorized Representative is willing and
able to provide signed informed consent or assent as appropriate

- Male or female adults 18 to 80 years of age, or adolescents 12 to 17 years of age

- Patients dependent on parenteral nutrition (PN) that receive PN for an average ≥ 4
days a week for 10 weeks or longer prior to screening to meet nutritional, caloric,
fluid, and/or electrolyte needs

- The Investigator expects no changes in the lipid, dextrose, amino acid, or vitamin
regimen to be medically necessary during the participant's participation in the study

- Willingness of participant to maintain his/her current habitual oral diet and fluids
regimen for the study duration


Exclusion Criteria:


- Participants taking steatogenic medications for ≥12 weeks in the past 12 months (e.g.,
amiodarone, tamoxifen, methotrexate, tetracycline, glucocorticoids, anabolic steroids,
over the usual dose of estrogen for hormone replacement therapy, and valproate); those
taking any medicine (e.g., metformin, thiazolidinediones, ursodeoxycholic acid,
pentoxifylline, S-adenosyl-L-Methionine, and betaine) that could affect the
measurement of IFALD within 12 weeks prior to study entry

- Participants taking potential hepatotoxic medications that in the judgement of the
Investigator is causing hepatic abnormalities

- Participants with a cardiac pacemaker, intravascular stents, other metallic devices,
and claustrophobia which are contraindicated to magnetic resonance imaging

- Participants who took choline supplements or choline-containing multivitamins within
14 days of screening

- History of major organ transplant (e.g., heart, kidney, liver, etc.)

For more information on eligibility criteria, please contact the sponsor.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 11/2/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Validation and Reliability of a Single Operator Technique for Stress Sonography in Healthy Elbow Medial Ulnar Collateral Ligaments (UCLUS)

Ulnar Ligament Ultrasound Stress Test

Jacob Sellon
Male
18 years to 40 years old
Not Applicable
This study is NOT accepting healthy volunteers
2021-305767-H01-RST
21-009058
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Males, age 18-40 years old.
  • Staff members and trainees within the Sports Medicine Division and Physical Medicine and Rehabilitation Departments of Mayo Clinic.


Exclusion Criteria:

  • Individuals under 18 or over 40 years old.
  • Prior or current history of elbow joint pain, injury, or surgery such as elbow joint arthritis, prior/current elbow ulnar collateral ligament injury that required subject to take time off from sport, or history of any elbow surgery.

Eligibility last updated 8/31/21. Questions regarding updates should be directed to the study team contact.

 

Orthopedic US scan, Ultrasonography of forearm, Ultrasonography of joint of upper extremity, Diagnostic Test
Elbow instability, Joint instability
Elbow joint unstable, Ultrasound, Musculoskeletal system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Phase I Study of Nab-paclitaxel/STI-3031 Complex (AP160-Complex) in Patients with Advanced Solid Tumors (MC210104)

A Study of AP160-Complex in Advanced Solid Tumors

Matthew Block
All
18 years and over
Phase 1
This study is NOT accepting healthy volunteers
2021-305772-P01-RST
22-000906
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Age ≥ 18 years.
  • Patients with histologically or cytologically confirmed advanced or metastatic non-neurological solid tumors, who have no curative or life prolonging therapeutic options AND a minimal level of tumor staining for PDL1 (clinical test using 22c3 immunohistochemistry) demonstrating tumor staining in ≥ 1% of tumor cell.
  • At least one prior systematic therapy in the metastatic setting (adjuvant or neoadjuvant therapy not included);
    • NOTE: There is no upper limit to the number of prior treatment regimens.
  • ECOG Performance Status (PS) 0, 1 or 2.
  • The following laboratory values obtained ≤ 14 days prior to registration:
    • Hemoglobin ≥ 9.0 g/dL (patients may be transfused to meet Hgb requirement);
    •  Absolute neutrophil count (ANC) ≥ 1500/mm^3;
    • Platelet count ≥ 100,000/mm^3;
    • Total bilirubin ≤ 1.5 x ULN or direct bilirubin ≤ 0.4 mg/dL;
    • SGOT (AST) ≤ 2.5 x ULN or ≤ 5 x ULN in case of liver metastases;
    • Alkaline phosphatase ≤ 2.5 x ULN or ≤ 5 x ULN in case of liver metastases;
    • Calculated creatinine ≤ 1.5 x ULN or Calculated creatinine clearance ≥45 ml/min using the Cockcroft-Gault formula below for subjects with creatinine >1.5 ULN:
      • Creatinine clearance for males = (140
        •age) (weight in kg) (72) (serum creatinine in mg/dL);
      • Creatinine clearance for females = (140
        •age) (weight in kg) (0.85) (72) (serum creatinine in mg/dL).
  • Negative serum pregnancy test done ≤ 7 days prior to registration, for women of childbearing potential only.
    • NOTE:   If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Provide written informed consent.
  • No motor peripheral neuropathy.
  • Sensory peripheral neuropathy ≤ Grade 1 (per CTCAE 5.0).
  • Immune-related adverse events (irAEs) from prior treatment have returned to baseline or ≤ Grade 1.
  • For persons of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for 6 months after the last dose of study treatment.
  • For person able to father a child: agreement to remain abstinent (refrain from heterosexual intercourse with a person of childbearing potential) or use contraceptive measures, and agreement to refrain from donating sperm during the treatment period and for 6 months after the last dose of study treatment.
  • Willingness to provide mandatory blood specimens for correlative research.
  • Willingness to provide mandatory tissue specimens for correlative research.
  • Willing to return to enrolling institution for follow-up 2-4 weeks after treatment discontinuation.
  • Life expectancy ≥ 90 days (3 months).

Inclusion Criteria Specific to Dose Expansion Cohorts

  • NOTE: Melanoma Dose Expansion cohort only planned for now. Availability to add other disease-specific Dose Expansion cohorts possible in future protocol amendments.
  • For Dose Expansion Cohort:
    • Measurable disease defined as at least one lesion whose longest diameter can be accurately measured as ≥ 2.0 cm with chest x-ray, or as ≥ 1.0cm with CT scan or MRI scan; or CT component of a PET/CT;
      • NOTE: Disease that is measurable by physical examination only is not eligible.
  • Melanoma Dose Expansion Cohort:
    • Histologic proof of surgically unresectable stage IV malignant melanoma;
    • Disease progression on or after anti-PD1/PDL1 antibody-based therapy in the metastatic setting (adjuvant or neoadjuvant therapy with anti-PD1/PDL1 antibody do not count).

Exclusion Criteria

  • Any of the following because this study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown:
    • Pregnant persons;
    • Nursing persons;
    • Persons of childbearing potential {and persons able to father a child} who are unwilling to employ adequate contraception.
  • Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy.
  • Any anti-cancer therapy or investigational agents ≤- 4 weeks prior to registration.
  • Failure to recover from prior surgery.
  • Failure to fully recover from acute, reversible effect of prior chemotherapy regardless of interval since last treatment.
  • Anti-PD(L)1 antibody ≤ 4 weeks prior to registration.
  •  Previous grade 4 irAEs from immune checkpoint inhibitor antibody therapy.
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  •  Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy;
    • NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial.
  • Uncontrolled intercurrent illness including, but not limited to:
    • ongoing or active infection;
    • symptomatic congestive heart failure;
    • unstable angina pectoris;
    • cardiac arrhythmia;
    • or psychiatric illness/social situations that would limit compliance with study requirements.
  • Other medical conditions including be not limited to:
    • History of liver disease such as cirrhosis, chronic active hepatitis, chronic persistent hepatitis or hepatitis B or C;
    • Active infection requiring parenteral antibiotics;
    • Active tuberculosis or active, non-infectious pneumonitis;
    • Evidence of interstitial lung disease;
    • New York Heart Association class II-IV congestive heart failure (Serious cardiac arrhythmia requiring medication);
    • Myocardial infarction or unstable angina ≤ 6 months prior to registration;
    • Congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.
  • Active autoimmune disease such as Crohn’s disease, rheumatoid arthritis, Sjögren’s disease, systemic lupus erythematosus, or similar conditions requiring systemic therapy within the past 2 years with the use of disease modifying agents, corticosteroids, or immunosuppressants or a documented history of clinically severe autoimmune disease/syndrome difficult to control in the past;
    •               EXCEPTIONS (the following are allowed):
      • Vitiligo or resolved childhood asthma/atopy;
      • Intermittent use of bronchodilators or local steroid injections;
      • Non-immunosuppressive maintenance treatments in the setting of clinically asymptomatic disease (e.g., sulfasalazine for ulcerative colitis);
      • Hypothyroidism or hypoadrenalism, stable on hormone replacement;
      • Diabetes stable with current management;
      • History of positive Coombs’s test but no evidence of hemolysis;
      • Psoriasis not requiring systemic treatment;
      • Conditions not expected to recur in the absence of an external trigger;
      • Secondary adrenal insufficiency from previous hypophysitis, currently on physiologic replacement steroid dosing only.
  •  Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm.
  • Other active malignancy ≤ 3 years prior to registration. Patients must not be receiving chemotherapy or immunotherapy for another cancer. Patients must not have another active malignancy requiring active treatment:
    • EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix:
      • NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment;
      • NOTE: Early-stage cancer (stage 1/2, treated) should be allowed.
  • History of myocardial infarction ≤ 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.
  • Active CNS metastasis;
    • NOTE: Patients with prior brain metastases that are asymptomatic without corticosteroid use and stable or improved ≥30 days after treatment with surgery or radiation are not excluded.
  • Corticosteroid use ≤ 14 days prior to registration;
    • NOTE: Patients must be off systemic corticosteroids for at least 2 weeks prior to registration. This includes oral or IV route of administration. Patients on chronic corticosteroids for adrenal insufficiency or other reasons may enroll if they receive less than 10 mg/day of prednisone (or equivalent). Patients receiving inhaled or intranasal or intra-articular steroids are not excluded;
    • EXCEPTIONS: Patients requiring steroid premedication for radiology contrast allergy are not excluded.
Drug
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Prospective Observational Study of Patient-Reported and Clinical Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma (TCR MM) (A MagnetisMM-Real World [RW] Study) (MagnetisMM-RW)

A study of how current treatments impact the course of relapsed myeloma and the effect of the treatments on the quality-of-life measurements.

Shaji Kumar
All
18 years and over
This study is NOT accepting healthy volunteers
2021-305783-P01-RST
21-009198
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Male or female age ≥ 18 years.
  • Prior diagnosis of multiple myeloma according to IMWG criteriaa , and measurable disease.
  • Relapsed MM refractory to at least one IMiD, PI, and anti-CD38 antibody; patient does not need to be refractory to all three classes of treatment in the same LOT in order to be eligible.
    • Note: Refractory is defined as having progressive disease (PD) while on therapy or within 60 days following treatment.
    • Note: PD will be defined as one or more of the following based on the 2016 IMWG consensus criteria for response and minimal residual disease assessment in MM:
      • Increase of 25% from lowest confirmed response value in one or more of the following criteria:
      • Serum M-protein (absolute increase must be ≥ 0.5 g/dL);
      • Serum M-protein increase ≥ 1 g/dL, if the lowest M component was ≥ 5 g/dL;
      • Urine M-protein (absolute increase must be ≥ 200 mg/24 h);
      • In patients without measurable serum and urine M-protein levels, the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be > 10 mg/dL);
      • In patients without measurable serum and urine M-protein levels and without measurable involved FLC levels, bone marrow plasma-cell percentage irrespective of baseline status (absolute increase must be ≥ 10%);
      • Appearance of a new lesion(s), ≥ 50% increase from nadir in the sum of the products of the maximal perpendicular diameters of measured lesions of > 1 lesion, or ≥ 50% increase in the longest diameter of a previous lesion > 1 cm in short axis; ≥ 50% increase in circulating plasma cells (minimum of 200 cells per µL) if this is the only measure of disease.
  • Relapsed or refractory to last anti-MM regimen.
  • ECOG performance status ≤ 2.
  • Receiving subsequent treatment after becoming TCR (but not necessarily the first subsequent treatment), where initiation of this treatment will define the index date.
  • Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
  • * If application of International Myeloma Working Group (IMWG) criteria for diagnosis of MM or assessment of response is not available as part of regular clinical practice, clinician assessment may be used. The specific criteria used will be documented in the case report form.


Exclusion Criteria:

  • Diagnosis of current smoldering MM, active plasma cell leukemia, amyloidosis, and Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes (POEMS) syndrome.
  • Prior stem cell transplant within 12 weeks prior to study enrollment or active graft-versus-host-disease (GVHD).
  • Any other active malignancy within 3 years prior to study enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
  • No investigational drug within 30 days or 5 half-lives preceding the index date, and throughout course of the study.
  • Prior or concomitant treatment with an anti-BCMA bispecific antibody, including PF-06863135.
  • Currently pregnant or breastfeeding.
    • Note: Additional inclusion/exclusion criteria may be applied in a sensitivity analysis to more closely match the Phase 2 MagnetisMM-3 (study C1071003) trial population depending on available data.
  • The following information will be collected at the time of enrollment to the extent data are available. Laboratory measurements will be based on the most recent reading at the time of enrollment:
    • Left ventricular ejection fraction (LVEF) > 40% by a multigated acquisition (MUGA) scan or echocardiogram (ECHO);
    • Adequate hepatic function;
    • Total bilirubin < 2 x upper limit of normal (ULN) (< 3 x ULN if documented Gilbert’s syndrome);
    • Aspartate transaminase (AST) < 2.5 x ULN; and
    • Alanine aminotransferase (ALT) < 2.5 x ULN;
    • Adequate renal function;
    • Creatinine clearance > 30 mL/min (according to the Cockcroft Gault formula, by 24-hour urine collection for creatinine clearance, or according to local institutional standard method;
    • Adequate bone marrow function o Absolute neutrophil count (ANC) > 1.0 x 10^9 /L;
    • Platelets > 25 x 10^9 /L; and
    • Hemoglobin > 8 g/dL;
    • Resolved acute effects of any prior therapy to baseline severity or Common Terminology Criteria for Adverse Events (CTCAE) Grade < 1.
  • History of impaired cardiovascular function or clinically significant cardiovascular diseases (CVD), defined as any of the following within 6 months prior to study enrollment:
    • Acute myocardial infarction (AMI) or acute coronary syndromes (e.g., unstable angina, coronary artery bypass graft, coronary angioplasty or stenting, symptomatic pericardial effusion);
    • Clinically significant cardiac arrhythmias (e.g., uncontrolled atrial fibrillation or uncontrolled paroxysmal supraventricular tachycardia);
    • Thromboembolic or cerebrovascular events (e.g., transient ischemic attack, cerebrovascular accident, deep vein thrombosis [unless associated with a central venous access complication] or pulmonary embolism);
    • Prolonged QT syndrome (or triplicate average QTc corrected using Fridericia’s formula [QTcF] > 470 msec at screening);
    • Presence of ongoing Grade > 2 peripheral sensory or motor neuropathy;
    • History of any grade peripheral sensory or motor neuropathy, collected among patients with prior BCMA-directed therapy;
    • History of Guillain-Barré syndrome (GBS) or GBS variants, or history of any Grade > 3 peripheral motor polyneuropathy.
  • Presence of surgical (including major surgery within 14 days prior to study enrollment), medical or psychiatric conditions including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the individual inappropriate for the study.
  • Presence of active hepatitis B virus (HBV), hepatitis C virus (HCV), SARS-CoV-2, human immunodeficiency virus (HIV), or uncontrolled infection. Active infections must be resolved at least 14 days prior to study enrollment.
  • Prior treatment with investigational drug within 30 days or 5 half-lives preceding the index date.

Eligibility last updated 2/14/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Single-cell Gastric Epigenomics and Transcriptomics in Humans

Gastric Epigenome and Transcriptome in Humans

Adil Bharucha
All
18 years and over
This study is NOT accepting healthy volunteers
2021-305786-H01-RST
20-012002
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Male or female patients, aged 18 years and older.
  • Scheduled to undergo gastric surgery for obesity.
  • Able to provide written informed consent before participating in the study.
  • Able to communicate adequately with the investigator and to comply with the requirements for the entire study.


Exclusion Criteria:

  • Individuals < 18 years old.
  • Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study.
  • Medications. Opiates and high doses of anticholinergic agents (e.g., amitriptyline greater than 50 mg daily).
  • Any other condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study.

Eligibility last updated 9/1/21. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Novel Mechanism of Hidradenitis Suppurativa: A Neuroendocrine Interaction Between Mast Cells, HPA Axis and Endocannabinoid System

Neuroendocrine System in HS

Afsaneh Alavi
All
18 years to 100 years old
This study is NOT accepting healthy volunteers
2021-305802-P01-RST
21-007888
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Male or female, at least 18 years old.
  • Subjects with diagnosis of Hidradenitis Suppurativa (HS) and at least one active inflammatory lesion (nodule, abscess or tunnel) and has indication for deroofing or surgery.
  • Subject must be in general good health without uncontrolled significant co-morbid conditions (except for hidradenitis suppurativa) as judged by the investigator, based on medical history.
  • Has/will have undergone surgery for HS treatment at the Department of Dermatology, Mayo Clinic between September 2021 and December 31, 2022


Exclusion Criteria:

  • Individuals < 18 years old.

Eligibility last updated 9/10/21. Questions regarding updates should be directed to the study team contact.

 

 

 

 

 

 

Inclusion Criteria:

-           -          

 

 

 


Exclusion Criteria:
 

  • Current use of any biologics, mast cell stabilizer or investigational drug within 4 weeks prior to skin sample, or 5 pharmacokinetic/pharmacodynamics half-lives, if known (whichever is longer)
  • Patients who have the comorbidities listed below:
    • Mast cell disorder
    • Active infection
    • Malignancy
    • Pregnancy
    • Major dermatitis (e.g. atopic dermatitis, psoriasis)
  • Patients whose records are incomplete

 

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

The Benefit of Mindfulness-Based Intervention Using A Wearable Wellness Brain Sensing Device (Muse-S™) in the Treatment of Post-Covid Symptoms

Mindfulness Intervention for Post-Covid Symptoms

Ivana Croghan
All
18 years and over
Feasibility
This study is NOT accepting healthy volunteers
2021-305823-H01-RST
21-009820
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:
 

  • 18 years of age or older at time of consent.
  • Identified with one of 3 Post-Covid Syndrome (PASC) phenotypes at Mayo Clinic Rochester:  
    • fatigue-predominant  (N=20);
    • pain-predominant  (N=20); 
    • orthostasis-predominant  (N=20).
  • Not pregnant by subject self-report at time of consent.
  • Have the ability to provide informed consent.
  • Have the ability to complete all aspects of this trial.
  • Have access to an iPhone, iPad, or Android device.  
  • Have no contraindicating comorbid health condition which would interfere with the proper use of the Muse-S™ system, as determined by the clinical investigators.


Exclusion Criteria:
    

  • Individuals < 18 years old.
  • Used an investigational drug within the past 30 days.
  • Anyone that is not on a stable dose of medication for anxiety, depression or sleep.
  • Currently (within the past 3 weeks) been practicing mindfulness training on a weekly/regular basis.
  • Currently (within 3 weeks) has been enrolled in another clinical or research program which intervenes on the patients’ QOL, or stress.
  • An unstable medical or mental health condition as determined by the physician investigator.

Eligibility last updated 2/1/22. Questions regarding updates should be directed to the study team contact.

 

Device
Coronavirus disease 2019, General infectious diseases, Post-COVID-19 syndrome
COVID-19, Chronic post-COVID-19 syndrome, Disease caused by 2019 novel coronavirus, Post-acute COVID-19, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration

UBX1325 for Treatment of Neovascular ARMD

Matthew Starr
All
50 years and over
Phase 2
This study is NOT accepting healthy volunteers
2021-305828-P01-RST
21-009324
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients aged ≥ 50 years.
  • Active CNV associated with age-related macular degeneration as evidenced on FA and SD-OCT with presence of intraretinal or subretinal fluid at Screening with either the CNV or fluid involving the center of the fovea.
  • Neovascular AMD patients who have had at least 3 anti-VEGF treatments in the study eye in the preceding 6 months prior to Screening, no less often, than approximately every 2 months
  • BCVA in the study eye (most affected) of 70 to 20 ETDRS letters (equivalent to 20/40 to 20/400 on the Snellen chart) at Screening and at Day 1. On Day 1, BCVA cannot be 10 or more letters from Screening:
    • Note: if both eyes are eligible, the one with the poorer BCVA should be chosen. If BCVA is equal, the eye with the greatest potential for vision gains, in the opinion of the Investigator, should be selected.
  • BCVA in the non-study eye of 35 ETDRS letters (equivalent to 20/200 on the Snellen chart) or better.
  • IOP ≤ 23 mmHg in the study eye.
  • Clear ocular media and adequate pupillary dilation to permit CFP, SD-OCT, and adequate BCVA evaluation.
  • Patients who have the capacity to give informed consent and who are willing and able to comply with all study-related procedures and assessments.


Exclusion Criteria:

  • Concurrent disease in the study eye or structural damage, other than nAMD, that could compromise BCVA, prevent BCVA improvement, require medical or surgical intervention during the study period, confound interpretation of the results, or interfere with assessment of toxicity or CFP in the study eye. This includes, but is not limited to, the following:
    • Macular edema of etiologies other than nAMD;
    • Clinically significant subretinal fibrosis;
    • Subfoveal lipid with atrophy involving center of fovea;
    • Cataract requiring surgery during the study period;
    • RPE atrophy or tear or rips involving the macula;
    • Presence of macular hole;
    • History of uveitis;
    • Vitreomacular traction;
    • Clinically significant epiretinal membrane (ERM);
    • Aphakia or Anterior Chamber Intraocular Lens (A/C IOL);
    • Other retinovascular disease.
  • Any ocular/intraocular/periocular infection or inflammation in either eye in the past 4 weeks prior to Screening (mild blepharitis is acceptable)
  • Subretinal hemorrhage with bleeding area ≥ 4 disc area in the study eye
  • History of vitrectomy in the study eye
  • History of intraocular, periocular, or corneal surgery in the study eye within 3 months prior to screening, or anticipated need for such surgery during the study
  • History of panretinal photocoagulation (within 6 months) or macular laser photocoagulation (within 3 months) in the study eye prior to Day 1
  • History of corneal transplant in the study eye
  • Concomitant use of > 2 medications for the treatment of glaucoma and unstable glaucoma in the study eye (i.e., inadequate IOP control). Combination drugs, if given in a single drop, are considered 2 medications
  • Any condition, including laboratory findings and findings in the medical history or in the pre-study assessments, that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation or prevent the patient from fully participating in all aspects of the study
  • Presence of severe myopia (-8 diopters or greater) in the study eye
  • The use of intraocular steroids in the study eye within the last 2 years prior to screening
  • History of Visudyne® photodynamic therapy in the study eye
  • Significant media opacities, including cataract, which might interfere with visual acuity, assessment of toxicity, or fundus imaging 
  • Intraocular surgery, including cataract surgery, in the study eye ≤ 3 months of screening
  • Known allergy to any component (phosphate buffered saline and polysorbate 80) of the Study Drug or to any component of Aflibercept, or a clinically relevant sensitivity to fluorescein dye
  • Female patients who are pregnant, lactating, or of childbearing potential who do not agree to use highly effective methods of birth control (e.g., progesterone-only hormonal contraception, double barrier, or intrauterine device) during the study and for 3 months following the last dose of Study Drug. Postmenopausal females (> 45 years old and without menses for more than 1 year) and surgically sterilized females are exempt from these requirements.
  • Male patients who do not agree to use a highly effective method of contraception during the study and for 3 months following the last dose of Study Drug, if sexually active with a female partner of childbearing potential.
  • Patients who within 3 months of screening received or are concurrently on another investigational drug or vaccine study, including patients who previously received treatment in a UBX1325 study. Coronavirus Disease 2019 (COVID-19) vaccinations are permitted prior to or during the course of the study.
  • Any uncontrolled medical condition, in the opinion of the Investigator, would preclude participation in this study, including, but not limited to, history of malignancy within the last 3 years (however, non-facial, basal cell carcinoma is allowed), history of myocardial infarction within the last 6 months, or concomitant therapy.

Eligibility last updated 9/3/21. Questions regarding updates should be directed to the study team contact.

 

Drug
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Randomized, Double-blind, Placebo Controlled, Dose Escalation Pilot Study Evaluating the Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial lung disease-related Cough (MACS-02)

Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough (MACS-2)

Vivek Iyer
All
18 years to 85 years old
Not Applicable
This study is NOT accepting healthy volunteers
2021-305848-H01-RST
21-009475
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

Subjects who meet all the following criteria will be eligible for the study:

  • Women and men between 18 and 85 years of age.
  • Have a diagnosis of interstitial lung disease (ILD) according to the American Thoracic Society Guidelines.
  • Have a chronic cough for at least 3 months prior to the screening visit.
  • Patients should be on a stable dose of ILD-directed therapies for 3 months prior to enrollment and will be allowed to continue their ILD-directed therapies. These include –but are not limited to- corticosteroids, immunosuppressing agents such as azathioprine and mycophenolate, as well as antifibrotic medications including nintedanib and pirfenidone. Additional corticosteroids and adjustment of ILD-directed therapy doses is permitted if deemed appropriate by the treating physician.
  • Have a score of ≥ 40mm on the Cough Severity VAS at Screening..
  • Women of child-bearing potential must use 2 forms of acceptable birth control and make no donation of eggs from Screening through the end of the 8-week study period. Acceptable birth control methods include established use of oral, injected, or implanted hormonal methods of contraception; intrauterine device (IUD) or intrauterine system (IUS); tubal ligation; or male sterilization. Double-barrier method (diaphragm for female subject and condom for male partner with spermicidal) satisfies the requirement for 2 forms of acceptable birth control. When concordant with the preferred lifestyle of the subject, true and complete abstinence (not periodic abstinence) is acceptable.
  • Male subjects and their partners of child-bearing potential must use 2 methods of acceptable birth control, 1 of which must be a barrier method, and make no donation of sperm from Screening until 3 months after the last dose of study drug at the end of 8 weeks.
  • Have provided written informed consent.
  • Are willing and able to comply with all aspects of the protocol.


Exclusion Criteria:

Subjects are NOT eligible for this study if they meet any of the following criteria:

  • Current smoker (cigarettes, e-cigarettes or marijuana) or former smokers who have smoked within the past 12 months.
  • Former smokers with > 20 pack-year history of smoking.
  • Ongoing treatment with an ACE-inhibitor that is considered as the potential cause of a subject’s cough or requiring treatment with an ACE-inhibitor during the study or within 12 weeks prior to the Screening/Baseline Visit (Day -14 to Day 0).
  • History of upper or lower respiratory tract infection or recent significant change in pulmonary status within 4 weeks of the Screening/Baseline Visit (Day -14 to Day 0).
  • History of opioid use specifically prescribed for chronic cough within 2 weeks of the Screening/Baseline Visit (Day -14 to Day 0). Use of opioids for other indications (for example, to treat pain) is permitted.
  • History of baclofen use specifically prescribed for chronic cough within 2 weeks of the Screening/Baseline Visit (Day -14 to Day 0). Use of baclofen for other indications (for example, to treat spasticity) is permitted.
  • Presence of an untreated or undertreated cause (other than ILD) for the patient’s chronic cough (per ACCP guidelines). e.g. uncontrolled asthma, GERD or post-nasal drainage that could potentially explain the patient’s chronic cough.
  • Requiring concomitant therapy with prohibited medications.
  • Treatment with any pharmaceutical or biological investigational therapy (excluding COVID vaccination and COVID related monoclonal antibody therapy).
  • Participation in another clinical trial that does not allow co-enrollment within 4 weeks prior to the Screening/Baseline Visit (Day -14 to Day 0).
  • Total bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3x the upper limit of normal (ULN) during screening.
  • Serum creatinine < 30 mL/min, hemodialysis or peritoneal dialysis.
  • Advanced liver disease as defined by the presence of cirrhosis and/or signs of portal hypertension.
  • History of previous hypersensitivity or intolerance to Duloxetine & Amitriptyline (patients who have previously been on either amitriptyline or duloxetine for chronic cough or other reasons and have tolerated the medication will be offered participation regardless of previous response to therapy).
  • Currently pregnant or breastfeeding female subject.
  • Presence of any medical condition or disability that the investigators believe could interfere with the assessment of safety or efficacy in this trial or compromise the safety of the subject.
  • Planned or anticipated major surgical procedure or other activity that would interfere with the subject’s ability to comply with protocol-mandated assessments (e.g., extended travel) during the subject’s participation in the study. 
  • Currently taking either another SSRI, SNRI or MAO inhibitor which the patient cannot safely discontinue at least 2 weeks prior to the screening period.

Eligibility last updated 6/3/22. Questions regarding updates should be directed to the study team contact.

 

Drug, Other
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY) (REGENCY)

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis

Fernando Fervenza
All
18 years to 75 years old
Phase 3
This study is NOT accepting healthy volunteers
2021-305850-P01-RST
21-010402
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Signed Informed Consent Form.
  • Age 18-75 years at time of signing Informed Consent Form.
  • Ability to comply with the study protocol, in the investigator's judgment.
  • Active or active/chronic ISN/RPS 2003 Class III or IV proliferative LN by renal biopsy performed in the 6 months prior to screening or during screening:
    • One or more active glomerular lesions must be present;
    • Class V disease may be present in addition to Class III or IV;
    • The local biopsy report will be used to determine eligibility.
  • SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria, which are met by the presence of Class III or IV LN (above) and current or past positive antinuclear antibody (ANA) Positive ANA is defined by ANA at a titer of ≥ 1:80 on HEp-2 cells or an equivalent positive ANA test at least once. UPCR ≥ 1 on a 24-hour collection at screening
  • Receipt of at least one dose of pulse methylprednisolone IV (≥ 250 mg) or equivalent for treatment of the current episode of active LN during the 6 months prior to screening or during screening, or to be given on Day 1 prior to the first infusion.
    • A maximum of 3 g methylprednisolone IV or equivalent during the 4 weeks prior to screening or during screening is allowed.
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraception, as defined below: Women must remain abstinent or use two reliable methods of contraception, including at least one method with a failure rate of < 1% per year, during study treatment and for 18 months after the final dose of obinutuzumab or placebo and 6 weeks after the final dose of MMF. A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). The definition of childbearing potential may be adapted for alignment with local guidelines or regulations. Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation; male sterilization; established, proper use of hormonal contraceptives that inhibit ovulation; hormone-releasing intrauterine devices; and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm, as defined below: With a female partner of childbearing potential, men who are not surgically sterile must remain abstinent or use a condom plus an additional contraceptive method used by the female partner that together result in a failure rate of < 1% per year during the treatment period and for 90 days after the final dose of MMF. Men must refrain from donating sperm during this same period. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.


Exclusion Criteria:

  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 18 months after the final dose of obinutuzumab or placebo or within 6 weeks after the final dose of MMF.
  • Women of childbearing potential, including those who have had a tubal ligation, must have a negative urine pregnancy test at screening. Positive test results will be confirmed with a serum pregnancy test. Severe renal impairment, as defined by eGFR < 30 mL/min/1.73 m^2 (as estimated using the CKD-EPI equation) or the need for dialysis or renal transplantation.
  • Sclerosis in > 50% of glomeruli on renal biopsy.
  • Presence of rapidly progressive glomerulonephritis, defined by any of the following:
    • Crescent formation in ≥ 50% of glomeruli assessed on renal biopsy;
    • Sustained doubling of serum creatinine during the 2 months prior to screening;
    • The investigator’s opinion that the patient has rapidly progressive glomerulonephritis.
  • Receipt of any of the following excluded therapies:
    • Any anti-CD20 therapy such as rituximab, ocrelizumab, or ofatumumab less than 9 months prior to screening or during screening;
    • If an anti-CD20 therapy has been received between 9 and 12 months prior to screening, the peripheral CD19+ B-cell count must be ≥ 25 cells/µL;
    • Cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening;
    • Any biologic therapy (other than anti-CD20) such as, but not limited to, belimumab, ustekinumab, anifrolumab, secukinumab, or atacicept during the 2 months prior to screening or during screening;
    • Oral inhibitors of Janus-associated kinase (JAK), Bruton’s tyrosine kinase (BTK), or tyrosine kinase 2 (TYK2), including baricitinib, tofacitinib, upadacitinib, filgotinib, ibrutinib, or fenebrutinib or any investigational agent during the 2 months prior to screening or during screening;
    • Any live vaccine during the 28 days prior to screening or during screening.
  • Severe, active central nervous system SLE, including retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke, cerebellar ataxia, or dementia.
  • High risk for clinically significant bleeding or any condition requiring plasmapheresis, intravenous immunoglobulin, or acute blood product transfusions.
  • Significant or uncontrolled medical disease which, in the investigator’s opinion, would preclude patient participation.
  • HIV infection:
    • For patients with unknown HIV status, HIV testing will be performed at screening if required by local regulations.
  • Tuberculosis (TB) infection:
    • Testing for latent TB will be performed at screening if required by local regulations or in accordance with local clinical practice;
    • Latent TB after completion of appropriate treatment is not exclusionary.
  • Active infection of any kind, excluding fungal infection of the nail beds.
  • Any major episode of infection that also fulfills any of the following criteria:
    • Requires hospitalization during the 8 weeks prior to screening or during screening;
    • Requires treatment with IV antibiotics or anti-infectives during the 8 weeks prior to screening or during screening;
    • Requires treatment with oral antibiotics or anti-infectives during the 2 weeks prior to screening or during screening:
      • Antibiotics or anti-infectives given in the absence of a major episode of infection are not exclusionary.
  • History of serious recurrent or chronic infection.
  • History of progressive multifocal leukoencephalopathy (PML).
  • History of cancer, including solid tumors, hematological malignancies, and carcinoma in situ, within the past 5 years:
    • Patients with non-melanomatous carcinomas of the skin that have been treated or excised and have resolved are eligible.
  • Major surgery requiring hospitalization during the 4 weeks prior to screening or during screening.
  • Current alcohol or drug abuse or history of alcohol or drug abuse within 12 months prior to screening or during screening.
  • Intolerance or contraindication to study therapies, including any of the following:
    • History of severe allergic or anaphylactic reactions to monoclonal antibodies or known hypersensitivity to any component of the obinutuzumab infusion;
    • Intolerance or contraindication to oral or IV corticosteroids;
    • Intolerance to MMF;
    • Lack of peripheral venous access.
  • Any of the following laboratory parameters:
    • AST or ALT > 2.5 x ULN;
    • Amylase or lipase > 2 x ULN;
    • Neutrophils < 1.5 x10^3 /µL;
    • Positive hepatitis B surface antigen (HBsAg);
    • Patients who are HBsAg negative and hepatitis B core antibody (HBcAb) positive with no detectable hepatitis B virus (HBV) DNA are eligible but will require monthly HBV DNA monitoring until 12 months after the last dose of obinutuzumab or placebo.
  • Positive hepatitis C serology Patients with positive hepatitis C antibody test result with no detectable hepatitis C virus (HCV) RNA at least 6 months after completion of antiviral therapy are eligible but will require monthly HCV RNA monitoring until 12 months after the last dose of obinutuzumab or placebo.
  • Hemoglobin < 7 g/dL, unless caused by autoimmune hemolytic anemia resulting from SLE.
  • Platelet count < 25,000/µL.
  • Positive serum human chorionic gonadotropin measured at screening.

Eligibility last updated 9/9/21. Questions regarding updates should be directed to the study team contact.

 

 

Biologic/Vaccine, Other
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Randomized, Placebo-controlled, Double-blind, Multi-center Phase 2/3 Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients with Symptomatic Polycystic Liver Disease (HS-20-677)

A Randomized, Placebo-controlled, Double-blind, Multi-center Phase 2/3 Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients with Symptomatic Polycystic Liver Disease

Marie Hogan
All
18 years and over
Phase 2/3
This study is NOT accepting healthy volunteers
2021-305857-P01-RST
21-009647
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Voluntary and valid written informed consent to participate in the trial provided by the patient before any trial related procedures are performed.
  • Male or female patient, ≥ 18 years at screening.
  • Diagnosis of PLD (associated with ADPKD or isolated as in ADPLD) as defined by htTLV ≥ 2500 mL/m at screening.
  • Presence of at least 1 of the following PLD-related symptoms within 2 weeks before screening: bloating, fullness in abdomen, lack of appetite, feeling full quickly after beginning to eat, acid reflux, nausea, rib cage pain or pressure, pain in side, abdominal pain, back pain, shortness of breath after physical exertion, limited in mobility, concern about abdomen getting larger, dissatisfied by the size of abdomen.
  • Not a candidate for, or not willing to undergo, surgical intervention for hepatic cysts during the trial.
  • Female patients of childbearing potential must be willing to use an acceptable method of contraception from screening and during the entire trial.
  • Male patients must be willing to use condom as method of contraception from screening and throughout the trial unless they have been sterilized by vasectomy (with an appropriate post-vasectomy documentation of the absence of sperm in the ejaculate).


Exclusion Criteria:

  • Surgical intervention for PLD within 3 months before screening.
  • Treatment with an SSA within 3 months before screening.
  • Non-responsive to previous treatment of PLD with an SSA as per the Investigator’s assessment.
  • Cholelithiasis within 3 months before screening or previous medical history of cholelithiasis induced by SSAs unless treated with cholecystectomy.
  • Presence of extrahepatic cysts that, in the Investigator’s opinion, may prevent the patient from safely participating in the trial.
  • Severe kidney disease, as defined by estimated glomerular filtration rate (eGFR) 160 mmHg and/or diastolic blood pressure of >100 mmHg at screening.
  • Severe liver disease defined as liver cirrhosis of Child-Pugh class C.
  • Use of oral contraceptives or estrogen supplementation within 3 months before screening.
  • Poorly controlled diabetes (hemoglobin A1c ≥ 10%) at screening.
  • Patients with a known history of hypothyroidism, unless they have been on adequate and stable replacement thyroid hormone therapy for at least 3 months before the first dose of the IMP.
  • Uncontrolled hypertension defined by a systolic blood pressure of > 160 mmHg and/or diastolic blood pressure of > 100 mmHg at screening
  • History of significant cardiac disease or current diagnosis of cardiac disease indicating significant risk of safety for patients participating in the trial, such as uncontrolled or significant cardiac disease, including any of the following:
    • History of myocardial infarction, angina pectoris or coronary artery bypass graft within 6 months before screening;
    • Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block or high-grade atrioventricular block (e.g., bifascicular block, Mobitz type II and third-degree atrioventricular block);
    • Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
    • Risk factors for Torsades de Pointes including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure or history of clinically significant/symptomatic bradycardia;
    • Treatment with concomitant medication(s) with a "Known risk of Torsades de Pointes" per www.crediblemeds.org that cannot be discontinued or replaced by safe alternative medication at least 5 half-lives or 7 days (whichever is longer) before the first dose of IMP;
    • Patients with a baseline QTc interval corrected by Fridericia's formula (QTcF) > 450 msec for males and > 470 msec for females at screening.
  • Patients with vascular compromise, including, but not limited to, mesenteric thrombosis, portal hypertension and thrombocytopenia (platelet counts less than 100 x 10^9 /L).
  • Pregnant, lactating or planning to be pregnant during the trial.
  • Clinically significant laboratory abnormalities, which in the opinion of the Investigator may prevent the patient from safely participating in the trial.
  • History of solid organ transplantation.
  • Any known allergy, hypersensitivity or intolerance to octreotide or any related drug, or other components of CAM2029, or history of any drug hypersensitivity or intolerance that, in the opinion of the Investigator, would compromise the safety of the patient.
  • Contraindications to, or interference with, MRI assessments, as dictated by local hospital regulations.
  • Previously treated/randomized in the current clinical trial.
  • Participation in any other clinical trial to test an investigational drug or device within the last 30 days before screening or during the trial.
  • Any other contraindicated serious medical condition that, in the Investigator’s opinion, may prevent the patient from safely participating in the trial.
  • Any other current or prior medical condition that may interfere with the conduct of the trial or the evaluation of its results in the opinion of the Investigator.
  • Unwilling or unable to comply with the requirements of the protocol or in a situation or condition that, in the opinion of the Investigator, may interfere with participation in the trial.
  • On the staff, affiliated with, or a family member of the personnel directly involved with this trial.

Eligibility last updated 9/10/21. Questions regarding updates should be directed to the study team contact.

Drug, Other
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC) (ATTACC)

Study of RP-3500 With Niraparib or Olaparib in Advanced Solid Tumors

Siddhartha Yadav
All
18 years and over
Phase 1/2
This study is NOT accepting healthy volunteers
2021-305858-P01-RST
21-009516
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


- Male or female and ≥18 years-of-age at the time of signature of the informed consent

- Confirmed advanced solid tumors resistant or refractory to standard treatment

- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.

- Evaluable disease as per RECIST v1.1

- Next generation sequencing (NGS) report obtained in CLIA-certified or equivalent
laboratory demonstrating eligible tumor biomarkers.

- Submission of available tumor tissue or willingness to have a biopsy performed if safe
and feasible

- Acceptable hematologic and organ function at screening

- Negative pregnancy test for women of childbearing potential at Screening and prior to
first study drug.

- Ability to swallow and retain oral medications.


Exclusion Criteria:


- Prior therapy with an ATR or DNA-dependent protein kinase (DNA-PK) inhibitor.

- Chemotherapy, small molecule anticancer or biologic anticancer therapy given within 10
days or 5 half-lives (whichever is longer), prior to first dose of study drug.

- Use of radiotherapy (except for palliative reasons) within 7 days prior to first dose
of study drug.

- History or current condition, therapy, or laboratory abnormality that might confound
the study results, or interfere with the patient's participation for the full duration
of the study treatment.

- No other anticancer therapy is to be permitted while the patient is receiving study
treatment.

- Major surgery ≤28 days or minor surgical procedures ≤7 days prior to first study
treatment dose.

- Uncontrolled, symptomatic brain metastases.

- Uncontrolled high blood pressure

- History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) diagnosis

- Presence of other known active invasive cancers.

- Pregnant or breastfeeding women.

- Psychological, familial, sociological, or geographical conditions that do not permit
compliance with the study protocol and/or follow-up procedures outlined in the
protocol.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 11/22/22. Questions regarding updates should be directed to the study team contact.

Drug
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Electrophysiologic and Biosensor Signal Analysis of Patients and Controls (PSA)

Electrophysiologic and Biosensor Signal Analysis of Patients and Controls

Erik St. Louis
All
18 years and over
This study is NOT accepting healthy volunteers
2021-305864-H01-RST
21-010416
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

Subjects

  • Clinically or genetically confirmed diagnosis of a neurological, psychiatric, or medical condition of interest.
  • Age ≥ 18 years at time of diagnosis.

Controls

  • Healthy control participants, either a convenience sample of patient’s friends, acquaintances, or family members; or alternatively, community controls, or control outpatients seen at Mayo Clinic.
  • Age ≥ 18 years at time of survey.


Exclusion Criteria:

Subjects

  • Age < 18 years at time of diagnosis.
  • Inadequate familiarity with the English language.
  • Presence of any medical condition or surgical history that could affect the safety of the subject or interfere with study assessments, safety, or the ability of the subject to complete the evaluation per the judgment of the site principal investigator.

Controls

  • Age < 18 years at time of survey.
  • Inadequate familiarity with the English language.
  • Presence of any medical condition or surgical history that could affect the safety of the subject or interfere with study assessments, safety, or the ability of the subject to complete the evaluation per the judgment of the site principal investigator.
  • Personal history of the neurological, psychiatric, or medical conditions being studied.

Eligibility last updated 11/17/21. Questions regarding updates should be directed to the study team contact.

 

 

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

MC210601 Phase II Clinical Trial of PLX038 in Patients with Platinum-resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancer

PLX038 for the Treatment of Metastatic Ovarian, Peritoneal, and Fallopian Tube Cancers

Andrea Wahner Hendrickson
Female
18 years and over
Phase 2
This study is NOT accepting healthy volunteers
2021-305866-P01-RST
21-012233
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria
•Registration:

  • Age ≥ 18 years.
    • NOTE: Because no dosing or adverse event data are currently available on the use of PLX038 in patients <18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.
  • Histological confirmed high grade serous ovarian cancer consistent with ovarian, fallopian tube, or primary peritoneal carcinoma (NOTE: Any of these diseases are referred to in this protocol as “ovarian cancer”).
  • Recurrent high grade serous ovarian cancer that was initially platinum sensitive (i.e., had at least one platinum-free interval of at least 6 months before progression) is now platinum resistant.
  • No more than one prior line of therapy for platinum resistant disease.
    • NOTE: Prior PARP inhibitor therapy is allowed.
  • Measurable disease per RECIST 1.1.
  • Disease that is amenable to two biopsies.
  • Life expectancy greater ≥ 12 weeks.
  • ECOG Performance Status (PS) 0, 1 or 2.
  • The following laboratory values obtained ≤ 28 days prior to registration:
    • Hemoglobin ≥ 8.0 g/dL;
    • Absolute neutrophil count (ANC) ≥ 1500/mm^3;
    • Platelet count ≥ 100,000/mm^3;
    • Total bilirubin ≤ 1.5 x ULN;
    • Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 3 x ULN (≤ 5 x ULN for patients with liver involvement);
    • Calculated creatinine clearance ≥ 45 ml/min using the Cockcroft-Gault formula.
  • Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only.
  • Provide written informed consent.
  • Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).
  • Willingness to provide mandatory blood specimens for correlative research.
  • Willingness to provide mandatory tissue specimens for correlative research.

Exclusion Criteria
•Registration:

Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:

  • Pregnant persons.
  • Nursing persons.
  • Persons of childbearing potential who are unwilling to employ adequate contraception.
  • Histology other than high grade serous carcinoma.
  • Prior treatment restrictions.
  • Chemotherapy ≤ 4 weeks prior to registration.
  • Immunotherapy ≤ 4 weeks prior to registration.
  • Radiotherapy ≤ 4 weeks prior to registration.
  • Any other investigational therapy ≤ 4 weeks prior to registration.
  • History of prior or concurrent malignancy ≤ 2 years prior to registration.
    • Exceptions: If natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen.
  • Uncontrolled intercurrent illness including, but not limited to:
    • Myocardial infarction within 6 months of study entry;
    • NYHA class III or IV heart failure;
    • Uncontrolled dysrhythmias or poorly controlled angina;
    • History of serious ventricular arrhythmia (VT or VF) and/or factors that predispose to arrhythmia (e.g., heart failure, hypokalemia, family history of Long QT syndrome).
  • Known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents.
    • Exception: Patients should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification. To be eligible for this trial, patients should be class 2B or better.
  • Known HIV.
    • Exception: Patients on effective anti-retroviral therapy with undetectable viral load ≤ 6 months prior to registration are eligible for this trial.
  • Known hepatitis.
    • Exception: For patients with evidence of chronic hepatitis B virus infection the HepB viral load must be undetectable on suppressive therapy, if indicated, to be eligible.
    • Exception: Patients with a history of hepatitis C virus infection must have been treated and cured. Patients with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load.
  • Receiving any other investigational agent.
  • History of clinically significant gastrointestinal bleeding, colitis, or gastrointestinal perforation.
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • Requirement for anticoagulation treatment that increases INR or APTT above the normal range.
    • Exceptions: low dose DVT or line prophylaxis allowed.
  • Known CNS disease.
    • Exception: Patients with treated brain metastases are eligible if follow-up brain imaging after CNS directed therapy shows no evidence of progression.
  • Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determined that immediate CNS specific treatment is not required and is unlikely to be required during the 1st cycle of therapy.
  • Known Gilbert's syndrome or homozygous for the UGT1A1*28 variant allele or other relevant alleles with severely reduced UGT1A1 activity.
  • Patients who require treatment with UGT1A1 inhibitors during the planned period of investigational treatment with PLX038.
Drug
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

MarkVCID Validation in the General Community (MarkVCID2)

Validation of MarkVCID in the General Community

Ronald Petersen
All
60 years to 90 years old
This study is NOT accepting healthy volunteers
2021-305868-H01-RST
21-009529
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Male or female.
  • Aged 60 to 90 years, inclusive at Visit 1 Screen.
  • Clinical diagnosis of normal cognition, subjective cognitive decline, mild cognitive impairment or mild dementia ( CDR® ≤ 1.5).
  • Fluent in English or Spanish.


Exclusion Criteria:

  • Contraindications to MRI such as inability to fit inside the MRI scanner, difficulty with close or confined spaces or presence of MRI non-compatible implants such as pacemakers or aneurysm clips.
  • History of or current neurologic, psychiatric or medical disease that could confound the results of the study tests and procedures.
  • Clinical diagnosis of moderate or severe cognitive impairment or dementia, requiring assistance with basic activities of daily living.

Eligibility last updated 2/17/22.  Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Shared Decision Making For Patients Living With Fibromyalgia

Shared Decision Making For Fibromyalgia Patients

Arya Mohabbat
All
18 years and over
This study is NOT accepting healthy volunteers
2021-305869-H01-RST
21-010359
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria
•Patients:

  • Patient age 18 or above.
  • Confirmed diagnosis of fibromyalgia (FM).
  • Patient must be able to understand and provide informed consent and HIPAA authorization.
  • Able to speak and read English.

Exclusion Criteria
•Patients:

  • Patients < 18 years of age.
  • Inability to provide informed consent or HIPAA authorization.
  • Individuals that decline study participation.
  • Patients without a confirmed diagnosis of FM.

Inclusion Criteria
•Clinicians:

  • Clinicians providing care to eligible patients at the Fibromyalgia Clinic and division of General Internal Medicine (Mayo Clinic Jacksonville and Rochester).

Exclusion Criteria
•Clinicians:

  • Individuals that decline study participation.

Eligibility last updated 10/1/21. Questions regarding updates should be directed to the study team contact.

 

 

    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    Quantitative Analysis of Short-Term Follow-Up CT Scan in Patients Undergoing Bronchoscopic Lung Volume Reduction (BLVR) with Endobronchial Valves

    Postprocedural CT Scan in Patients Undergoing Bronchoscopic Lung Volume Reduction with Endobronchial Valves to Determine Benefit or Adverse Effects

    Tobias Peikert
    All
    18 years and over
    Not Applicable
    This study is NOT accepting healthy volunteers
    2021-305871-H01-RST
    22-001325
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • Age ≥ 18 years.
    • Subjects must have undergone bronchoscopic lung volume reduction with endobronchial valve(s) placement for treatment of emphysema at Mayo Clinic-Rochester within timeframe of 3/01/2022 to 2/28/2023.
    • Subjects must consent to undergoing CT scan of the chest prior to hospital discharge.


    Exclusion Criteria:

    • Previous endobronchial valve placement (i.e., undergoing secondary procedure to have additional valves placed or valves upsized).
    • Presence of large post-procedure pneumothorax, as defined by > 2 cm of air present between lung margin and chest wall measured at level of the hilum, identified prior to study CT acquisition.

    Eligibility last updated 3/1/22. Questions regarding updates should be directed to the study team contact.

    Diagnostic Test, Radiation
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    An Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-3745 in Participants with Glycogen Storage Disease Type 1a (GSD1a) (GSD1a)

    A Study of mRNA-3745 in Participants With Glycogen Storage Disease Type 1a (GSD1a)

    Eva Morava-Kozicz
    All
    18 years and over
    Phase 1
    This study is NOT accepting healthy volunteers
    2021-305874-P01-RST
    21-009551
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:


    - Documented GSD1a with confirmation by genetic testing

    - Documented history of ≥1 hypoglycemic event with blood glucose <60
    milligrams/deciliter (mg/dL) (<3.3 millimoles/liter [mmol/L]) and symptoms of
    hypoglycemia in the absence of acute illness, with at least one such event in the 4
    weeks before signing the Informed Consent.


    Exclusion Criteria:


    - Liver transplant, including hepatocyte cell therapy/transplant

    - Received gene therapy for GSD1a

    - Presence of liver adenoma >5 centimeters (cm) in size

    - Presence of liver adenoma with growth of >2 cm or >5 newly diagnosed liver adenoma, in
    the previous 2 years.

    Note: Additional inclusion/exclusion criteria may apply, per protocol.

    Eligibility last updated 6/8/22. Questions regarding updates should be directed to the study team contact.

     

     

    Drug
    Glycogen storage disease type Ia
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    Evaluation of the Hemp Serum IgE Antibody Assay for Potential Evaluation of Cannabis/CBD/Hemp-Related Product Allergy (ADL)

    Cannabis Allergy Study

    Joshua Bornhorst
    All
    18 years and over
    This study is NOT accepting healthy volunteers
    2021-305878-H01-RST
    21-009210
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria;

    • Individuals ≥ 18 years old.
    • Documentation by a doctor of allergic reactions upon cannabis exposure.


    Exclusion Criteria:

    • Individuals < 18 years old.
    • Currently undergoing anti-IgE drug treatment (e.g., Omalizumab).

    Eligibility last updated 12/3/21. Questions regarding updates should be directed to the study team contact.

    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+/HER2- Breast Cancer (ATOS-Z-201)

    (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

    Matthew Goetz
    Female
    18 years and over
    Phase 2
    This study is NOT accepting healthy volunteers
    2021-305880-P01-RST
    22-011685
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    Each patient must meet the following criteria to be enrolled in PK Run-in Cohort or the Treatment Cohort of this study:

    • Female sex assigned at birth.
    • ≥ 18 years of age.
    • Not lactating, pregnant, or planning to become pregnant in the next year and agrees to take adequate steps to prevent becoming pregnant 7 days before beginning treatment, during treatment and for 9 months after last dose and not breast feeding during treatment and for 3 months after last dose.
    • Must agree to one non-hormonal highly effective method of contraception for the entire duration of study participation. Highly effective methods of birth control are defined as those, alone or in combination, that resulted in a low failure rate of < 1% per year when used consistently and correctly such as intrauterine devices (IUDs, non-hormonal such as copper IUD), sexual abstinence or vasectomized partner. Barrier contraceptives (e.g., male condom or diaphragm) are acceptable if used in combination with spermicides (e.g., foam, gel).
    • Premenopausal defined as any female who has experienced menarche and does not meet any of the following criteria for postmenopausal:
      • Permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy); or
      • Amenorrheic for 12 or more months; or
      • Amenorrheic for < 12 or more months and follicle-stimulating hormone (FSH) or plasma estradiol are in the postmenopausal range.
    • Pathologic confirmation of strongly estrogen receptor positive (ER+) (defined as estrogen receptor [ER] ≥ 67% or Allred Score 6-8) by local institution protocol.
    • Eastern Cooperative Oncology Group ECOG Performance Status (ECOG PS) of 0 to 2.
    • Nottingham Grade 1 or 2.
    • HER2- breast cancer (histologically confirmed) using American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines defined as one of the following:
      • 0 or 1+ by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) not done;
      • 0 or 1+ by IHC and not amplified by FISH;
      • 2+ by immunohistochemistry with average of < 4.0 HER2 signals per cell and an HER2/CEP17 ratio ≥ 2.0;
      • 2+ by immunohistochemistry with average of ≥ 4.0 and < 6.0 HER2 signals per cell and an HER2/CEP17 ratio < 2.0;
      • IHC not done and not amplified by fluorescence in situ hybridization (FISH).
    • Clinical Stage IIA or IIB invasive breast cancer (per American Joint Committee on Cancer [AJCC] 8th edition clinical staging) see Appendix 10.
    • Largest tumor diameter2.0 cm either by imaging or clinical examination.
    • Magnetic resonance imaging (MRI) ≤ 30 days of registration.
    • Mammogram performed ≤ 90 days of registration (Treatment Cohort only).
    • Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
    • Willing to provide tissue samples for research purposes.


    Exclusion Criteria:
     

    Subjects who meet any of the following criteria will be excluded from the PK Run-in Cohort and the Treatment Cohort:

    • Inflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion.
    • Any prior diagnosis or treatment for breast cancer, including carcinoma in situ, or history of any other active malignancy within the past 2 years prior to study entry, with the exception of:
      • Adequately treated in situ carcinoma of the cervix uteri;
      • Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin;
      • Any other malignancy with a life expectancy of more than 2 years.
    • Any uncontrolled intercurrent illness including, but not limited to:
      • Ongoing or active infection requiring systemic treatment with strong inhibitors/inducers of CYP450 enzymes (including bacterial infection, fungal infection, or detectable viral infection).;
      • Symptomatic congestive heart failure;
      • Unstable angina pectoris;
      • Uncontrolled symptomatic cardiac arrhythmias;
      • Uncontrolled hypertension (defined as blood pressure > 160/90 mm Hg);
      • Uncontrolled diabetes (Hemoglobin A1c [HbA1c] > 50 mmol/mol);
      • Marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval > 470 milliseconds [msec]) using Fridericia’s QT correction formula seen ≤ 28 days of registration.
    • Any of the following co-morbid conditions:
      • Known cataracts or retinopathy;
      • History of deep vein thrombosis (DVT)/pulmonary embolism (PE);
      • Known activated protein C (APC) resistance, an inherited coagulation disorder.
    • Evidence of the following laboratory abnormalities ≤ 28 days prior to registration:
      • Creatine clearance < 60 ml/hr by the Cockcroft-Gault equation;
      • Total bilirubin ≥ 1.5 x upper limit of normal (ULN);
      • Aspartate aminotransferase (AST) or alanine amino transferase (ALT) ≥ 2.5 x ULN;
      • Platelet count (PLT) ≤ 75,000/mm^3 ;
      • Hemoglobin (Hb) ≤ 10 g/dL.
    • Hormonal therapies including birth control and hormone replacement therapy during the study or within 1 week of registration.
    • Allergy to endoxifen, goserelin, or exemestane or any of their components.
    • Participation in another investigational clinical trial ≤ 6 months of registration.
    • Not willing or able to understand the study information and/or informed consent.

    Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

    Eligibility last updated 11/7/22. Questions regarding updates should be directed to the study team contact.

    Drug
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    Safety and Feasibility of Intra-Cardiac Echocardiography in Guiding Left Atrial Appendage Occlusion with the Watchman Device: The ICE WATCHMAN study (WATCH-ICE)

    The ICE WATCHMAN Trial

    Mohamad Adnan Alkhouli
    All
    18 years and over
    Not Applicable
    This study is NOT accepting healthy volunteers
    2021-305887-H01-RST
    21-009613
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • Men and women, ≥ 18 years of age.
    • The patients is eligible to undergo WATCHMAN device implant procedure.
    • The patient is eligible for short term anticoagulation therapy.
    • Ability to tolerate the procedure without the need for general anesthesia as assessed by the treating physician(s).
    • Ability to give informed consent for the procedure.
    • The patient is able and willing to undergo the procedure under moderate sedation.
    • The patient is able and willing to return for required 45-day TEE.


    Exclusion Criteria:

    • Patient has contraindication for short term anticoagulation.
    • The patient has history of a hypercoagulable state per medical record documentation.
    • Pregnancy or planning to get pregnant during the investigation.

    Eligibility last updated 9/21/21. Questions regarding updates should be directed to the study team contact.

    Device, Procedure/Surgery
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    EA2201, A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma (EA2201)

    Testing Nivolumab and Ipilimumab With Short-Course Radiation in Advanced Rectal Cancer

    Zhaohui Jin
    All
    18 years and over
    Phase 2
    This study is NOT accepting healthy volunteers
    2021-305889-P01-RST
    21-009838
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • Patient must be ≥ 18 years of age.
    • Patient must have histologically confirmed adenocarcinoma of the rectum with the inferior margin within 15 cm from the anal verge based on colonoscopy and/or flexible sigmoidoscopy.
    • Patient must have T3-4Nx or TxN+ disease (stage II or III) based on magnetic resonance imaging of the pelvis and computed tomography of the chest and abdomen. These baseline scans must be done within 28 days prior to registration.
    • Patient must have MSI-H (microsatellite instability-high) or dMMR (deficient mismatch repair) tumors based on immunohistochemistry or PCR (polymerase chain reaction).
    • Patient must have Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.
    • Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible.
    • Patient must agree to not receive live vaccines while on this study.
    • Patients of childbearing potential and sexually active patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for at least one month (female patients) or one week (male patients) prior to the start of study drug and continue for 5 months after the last dose of study drug (for female patients). Investigators must counsel patients on the importance of pregnancy prevention and the implications of an unexpected pregnancy.
    • Leukocytes ≥ 3,000/mcL (must be obtained ≤ 14 days prior to protocol registration).
    • Absolute neutrophil count (ANC) ≥ 1,500/mcL (must be obtained ≤ 14 days prior to protocol registration).
    • Platelets ≥ 100,000/mcL (must be obtained ≤ 14 days prior to protocol registration).
    • Total bilirubin ≤ institutional upper limit of normal (ULN) (must be obtained ≤ 14 days prior to protocol registration).
    • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 x institutional ULN (must be obtained ≤ 14 days prior to protocol registration)
    • Creatinine ≤ 1.5 x institutional ULN (must be obtained ≤ 14 days prior to protocol registration).
    • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial.
    • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
    • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
    • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
    • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.


    Exclusion Criteria:

    • Patient must not have previously received chemotherapy or immunotherapy for rectal cancer.
    • Patient must not have previously received radiotherapy to the pelvis.
    • Patient must not have had major surgery performed within 28 days prior to registration.
    • Patient must not have a history of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan.
    • Patient must not have a serious active infection requiring IV antibiotics at time of registration.
    • Patient must not have active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including chronic prolonged systemic corticosteroids (defined as corticosteroid use of duration one month or greater). These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or anti-phospholipid syndrome. Patients with any of these are ineligible for this study because of the risk of recurrence or exacerbation of disease.
    • Patient must not have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to registration. Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted.
    • Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy. A repeat pregnancy test must be done within 72 hours prior to first dose of treatment if the baseline test was done outside the 72 hour window. A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:
      • has achieved menarche at some point;
      • has not undergone a hysterectomy or bilateral oophorectomy; or
      • has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

    Eligibility last updated 9/14/21. Questions regarding updates should be directed to the study team contact.

    Biologic/Vaccine, Radiation
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    Neostigmine and Glycopyrrolate for the Treatment of Post Dural Puncture Headache After Known Dural Puncture with a Touhy Needle: A Pilot Study

    Neostigmine and Atropine for the Treatment of Headache After Dural Puncture Placement

    Mark Rollins
    Female
    18 years to 50 years old
    Not Applicable
    This study is NOT accepting healthy volunteers
    2021-305890-H01-RST
    21-009530
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:


    - Post-dural puncture headache (PDPH) after documented dural puncture with Tuohy needle
    during placement of epidural analgesia for labor and no other explanation for headache
    (HA).

    - Onset of HA within 72 hours of delivery.


    Exclusion Criteria:


    - Patient refusal.

    - Visual analog scale (NRS) score < 4.

    - History of migraine headaches.

    - Asthma.

    - Arrhythmia.

    - Heart block.

    - Myasthenia gravis.

    - Inability to understand pain scores and other questionnaires.

    - Inability to speak English.

    - Contraindication to acetaminophen or NSAIDs.

    - Temperature > 38.5 C.

    - Prior EBP done for this HA.

    Note: Other protocol defined Inclusion/Exclusion criteria may apply.

    Eligibility last updated 9/21/22. Questions regarding updates should be directed to the study team contact.

    Drug
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of AMZ002, Compared to Vigabatrin, in the Treatment of Infantile Spasms (AMZ002)

    AMZ002 Compared to Vigabatrin

    Elaine Wirrell
    All
    2 months to 24 months old
    Phase 3
    This study is NOT accepting healthy volunteers
    2021-305892-P01-RST
    21-009655
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • Patient is male or female and is 2 months to 24 months of age, inclusive.
    • Patient has been diagnosed with IS within 6 weeks prior to Screening. Diagnostic criteria include both clinical spasms and an electroencephalogram (EEG) pattern consistent with hypsarrhythmia or significant abnormality compatible with IS.
      • NOTE: If a video EEG is performed at the clinical site within 48 hours prior to the patient's parent/guardian providing written informed consent, and it meets the criteria, this video EEG may be used as the screening/baseline EEG for the study.
    • Patient has normal renal function as defined by an estimated glomerular filtration rate (eGFR).
    • > 60 mL/min/1.73 m^2, calculated as eGFR = 0.413 x (height [cm]/ serum creatinine [mg/dL]).
    • Patient's legally authodzed representative (i.e., parent or guardian) must provide written informed consent obtained per Institutional Review Board policy and requirements, consistent with the International Council for Harmonisation.
    • Patient's parent/guardian is able to understand and willing to comply with study procedures and restrictions.


    Exclusion Criteria:

    • Patient has been diagnosed with tuberous sclerosis.
    • Patient has acute illness considered clinically significant by the Investigator within 30 days prior to Screening.
    • Patient has a diagnosis of recent systemic fungal infection; history of ocular herpes simplex; history of or current peptic ulcer; uncontrolled hypertension or congestive heart failure; or any other condition that would be significantly impacted by the study drug.
    • Patient has a preplanned surgery or procedurc(s) that would interfere with the conduct of the study.
    • Patient has received any prior treatment for IS.
    • Patient has been previously treated with adrenocorticotropic honnonc (ACTH), corticosteroids, or vigabatrin for seizures.
    • Patient has been previously treated with a course of corticosteroids for an indication other than seizures within 30 days prior to Screening.
    • Patient has a known or suspected allergy to ACTH or vigabatrin or any component of AMZ002 or vigabatrin.
    • Patient has used any other investigational drug within 30 days or 5 half-lives prior to the first dose of AMZ002 or vigabatrin (whichever is longer).
    • Patient's parent/guardian is unable to provide written informed consent and/or to complete the daily diary.
    • Patient has any other disease, condition, or therapy that, in the opinion of the Investigator, might compromise safety or compliance, preclude the patient from successfully completing the study, or interfere with the interpretation of the results.

    Eligibility last updated 9/15/21. Questions regarding updates should be directed to the study team contact.

    Drug
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    Elotuzumab in IgG4-Related Disease (IgG4)

    Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

    Shounak Majumder
    All
    18 years to 70 years old
    Phase 2
    This study is NOT accepting healthy volunteers
    2021-305917-P01-RST
    21-009754
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • Participant must be able to understand and provide informed consent and be willing to comply with study procedures and follow up.
    • Are at least 18 years of age and not older than 70 years of age at screening.
    • Meet the ACR/EULAR Classification Criteria for IgG4-RD.
    • Have active disease based at screening on an IgG4-RD RI ≥ 4, with disease manifestations in at least two organ systems.
    • May have newly-diagnosed or relapsing disease at screening. Relapsing disease is defined as IgG4-RD that has previously been in remission but is now active again.
    • May be on treatment or off treatment at the time of screening. If on treatment, must be willing to discontinue those other treatments before the baseline visit.
    • No history of severe allergic reactions to monoclonal antibodies.
    • Female participants of childbearing potential must have a negative pregnancy test upon study entry.
    • Female participants of childbearing potential and male participants with a partner of childbearing potential must agree to consistently and correctly use FDA approved highly effective methods of birth control, for the entire duration of the study.
    • Immunization with one of the FDA authorized or licensed SARS-CoV2 vaccines is required for study entry. Vaccination series must have been completed at least 2 weeks prior to start of study therapy.
    • Participants with COVID-19 infections within the preceding three months must have 2 consecutive negative nasal swab PCR tests performed at least 24 hours apart.


    Exclusion Criteria:

    • Presence of a condition other than IgG4-RD that (e.g., asthma) is likely to require systemic Glucocorticoids (GC) for disease control during the period of the trial.
    • Malignancy within 5 years (except successfully treated in situ cervical cancer, resected squamous cell or basal cell carcinoma of the skin.)
    • the following lab values as indicators of hepatic dysfunction:
      • Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than three times the upper limit of normal (ULN);
      • Total bilirubin > two times the ULN unless caused by Gilbert’s disease. Gilbert’s disease with total bilirubin > three times ULN;
      • Serum albumin < 2.5 mg/dL.
    • Evidence of another uncontrolled condition which, in the judgment of the investigator, could interfere with participation in the trial according to the protocol.
    • Active infection requiring hospitalization or treatment with systemic antimicrobial agents within the 30 days prior to randomization.
    • Prior use of rituximab or other B cell depleting agents within 9 months of enrollment unless B cells have been demonstrated to have repopulated.
    • Use of any investigational agent or biologic and non-biologic DMARDSwithin 5 half-lives of the agent (or 6 months if the half-life is unknown) prior to enrollment.
    • Any of the following laboratory tests at the Screening Visit:
      • White blood cell (WBC) count < 3.0 x 10^3/µL;
      • Absolute neutrophil count (ANC) < 1.5 x 10^3/µL;
      • Hemoglobin < 10 g/dL;
      • Platelet count < 75 x 10^9/L;
      • Estimated glomerular filtration rate (eGFR) ≤ 45 ml/minute/1.73m^2.
    • The use of supplemental oxygen at baseline.
    • Positive Quantiferon gold assay. Indeterminate Quantiferon gold assays must be repeated(with same or other interferon gamma release assay (IGRA) per local policy) and shown to be negative. Alternatively, if the Quantiferon gold assay remains indeterminant, a participant must have a negative PPD. Finally, if the participant has had the Bacille Calmette-Guerin (BCG) vaccine or has some other condition complicating the interpretation of TB testing, consultation with infectious disease specialist must be obtained before receipt of the first investigational infusion.
      • Participants diagnosed with latent TB are eligible but must have received appropriate prophylaxis for 30 days before their first investigational infusion.
    • Medical history or serologic evidence at Screening of chronic infections including:
      • Human immunodeficiency virus infection;
      • Hepatitis B as indicated by surface antigen or hepatitis B core antibody positivity;
      • Hepatitis C as indicated by anti-hepatitis C antibody positivity; if a participant is Hepatitis C antibody positive, they will be eligible to participate in the study if he/she is negative for viral load at Screening.
    • Live vaccines within 8 weeks of initiating study therapy.
    • Participantis pregnant or breastfeeding, or planning a pregnancy while enrolled in the study.
    • Substance use disorder, including the recurrent use of alcohol and/or drugs within the past year associated with clinically significant impairment associated with failure to meet major responsibilities at work, school, or home.
    • IgG4-RD that is dominated primarily by advanced fibrotic lesions. Specifically, participants whose disease manifestations consist only of:
      • retroperitoneal fibrosis;
      • fibrosing mediatinitis;
      • sclerosing mesenteritis; and
      • Riedel’s thyroiditis. Participants with these disease manifestations can be included; however, only if they have disease in 2 organ systems that is not of an advanced fibrotic nature and otherwise meet the Inclusion and Exclusion Criteria.

    Eligibility last updated 8/11/22. Questions regarding updates should be directed to the study team contact.

    Biologic/Vaccine, Drug, Other
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    Initial Correction Keratoconus: Scleral vs. Corneal Gas Permeable Lenses (SVGPL)

    SCOPE Study

    Muriel Schornack
    All
    18 years and over
    Not Applicable
    This study is NOT accepting healthy volunteers
    2021-305925-P01-RST
    21-009776
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • Age 18 or older.
    • Diagnosis of keratoconus.
    • Available baseline corneal topography and pachymetry.
    • Amsler-Krumeich keratoconus classification of stage 1 or higher.


    Exclusion Criteria:

    • No prior corneal transplantation or INTACTS.
    • No prior use of hybrid, corneal or scleral gas permeable lenses.
    • Presence of corneal scarring.

    Eligibility last updated 9/17/21. Questions regarding updates should be directed to the study team contact.

     

    Other
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    Study CDX 960P: Surveillance of Colorectal Dysplasia in Inflammatory Bowel Disease with WATS (Wide Area Transepithelial Sample with 3-Dimensional Computer-Assisted Analysis): A Proof of Principle Study (CDx WATS)

    Surveillance of Colorectal Dysplasia to Treat Inflammatory Bowel Disease with Wide Area Transepithelial Sample (WATS)

    Nayantara Coelho-Prabhu
    All
    18 years and over
    This study is NOT accepting healthy volunteers
    2021-305926-P01-RST
    21-009672
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • Both males and females will be enrolled and must be at least 18 years of age.
    • Patients with a known history of IBD and dysplasia (low grade or high grade) undergoing surveillance.
    • Only patients who undergo both WATS and standard biopsy will be included in this study.
    • Institutional Review Board (IRB)-approved consent must be signed by patients to participate in this study.


    Exclusion Criteria:

    • Individuals < 18 years of age.

    Eligibility last updated 2/7/22. Questions regarding updates should be directed to the study team contact.

     

    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    MC210301 Long Term Followup of Patients Enrolled in MC1137 (BEAUTY) (BEAUTY)

    Long-term Follow Up of Patients Previously Enrolled in MC1137 (BEAUTY)

    Judy Boughey
    Female
    18 years and over
    This study is NOT accepting healthy volunteers
    2021-305936-P01-RST
    21-010580
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    For patients still alive:

    • Enrolled in BEAUTY Study (MC1137) and did not withdraw consent while enrolled on BEAUTY for either specimen collection or long-term follow-up.
    • Able to provide written informed consent.
    • Willingness to provide mandatory blood specimens for future research on breast cancer at Mayo Clinic.
    • Willingness to provide mandatory tissue specimens for future research on breast cancer at Mayo Clinic.
    • Willingness to provide consent for use of archived tumor biopsies obtained after enrollment in BEAUTY (Request tissue from prior biopsy of site of recurrence).
    • Ability to complete questionnaires by themselves or with assistance.

    For patients who have died:

    • Enrolled in MC1137 and did not withdraw consent while enrolled on BEAUTY for either specimen collection or long-term follow-up.
    • Existence of a family member willing to provide consent for use of archived tumor biopsies obtained after enrollment in BEAUTY.


    Exclusion Criteria:
     

    • Not enrolled in BEAUTY study (MC1137).

    Eligibility last updated 6/30/22. Questions regarding updates should be directed to the study team contact.

     

    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic — Rochester, MN

    NRG-BR007, A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    Ron Smith
    All
    50 years to 70 years old
    Phase 3
    This study is NOT accepting healthy volunteers
    2021-305950-P01-MAIJ
    21-009845
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the U.S., authorization permitting release of personal health information.
    • The patient must have an ECOG performance status of 0 or 1.
    • The patient must have undergone a lumpectomy and the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS with no ink on tumor as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional excisions may be performed to obtain clear margins. (Patients with margins positive for LCIS are eligible without additional resection).
    • The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination.
    • Patient must have undergone axillary staging (sentinel node biopsy and/or axillary node dissection).
    • The following staging criteria must be met postoperatively according to AJCC 8th edition criteria:
      • By pathologic evaluation, primary tumor must be pT1 (less than or equal to 2 cm);
      • By pathologic evaluation, ipsilateral nodes must be pN0. (Patients with pathologic staging of pN0(i+) or pN0(mol+) are NOT eligible);
      • Oncotype DX Recurrence Score of less than or equal to 18 on diagnostic core biopsy or resected specimen;
        • ** For patients with a T1a tumor (less than or equal to 0.5 cm in size) who do not already have an Oncotype DX Recurrence Score at study entry, a specimen (unstained blocks or slides) must be sent to the Genomic Health centralized laboratory.
      • The tumor must have been determined to be ER and/or PgR positive assessed by current ASCO/CAP Guideline Recommendations for hormone receptor testing. Patients with greater than or equal to 1% ER or PgR staining by IHC are considered positive;
      • The tumor must have been determined to be HER2-negative by current ASCO/CAP guidelines.
    • Patients may be premenopausal or postmenopausal at the time of study entry. For study purposes, postmenopausal is defined as: age 56 or older with no spontaneous menses for at least 12 months prior to study entry; or a documented hysterectomy; or age 55 or younger with no spontaneous menses for at least 12 months prior to study entry (e.g., spontaneous or secondary to hysterectomy) and with a documented estradiol level in the postmenopausal range according to local institutional/laboratory standard; or documented bilateral oophorectomy.
    • The interval between the last surgery for breast cancer (including re-excision of margins) and study entry must be no more than 70 days.
    • The patient must have recovered from surgery with the incision completely healed and no signs of infection.
    • Bilateral mammogram or MRI within 6 months prior to study entry. HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
    • Patients must be intending to take endocrine therapy for a minimum 5 years duration (tamoxifen or aromatase inhibitor). The specific regimen of endocrine therapy is at the treating physician's discretion.


    Exclusion Criteria:

    • Definitive clinical or radiologic evidence of metastatic disease. -pT2
      •pT4 tumors including inflammatory breast cancer.
    • Pathologic staging of pN0(i+) or pN0(mol+), pN1, pN2, or pN3 disease.
    • Patient had a mastectomy.
    • Palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor.
    • Suspicious microcalcifications, densities, or palpable abnormalities (in the ipsilateral or contralateral breast) unless biopsied and found to be benign.
    • Non-epithelial breast malignancies such as sarcoma or lymphoma.
    • Proven multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or separated by 4 or more centimeters. (Patients with multifocal carcinoma are eligible).
    • Paget's disease of the nipple.
    • Any history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated or not treated. (Patients with synchronous or previous ipsilateral LCIS are eligible).
    • Synchronous or previous contralateral invasive breast cancer or DCIS. (Patients with synchronous and/or previous contralateral LCIS are eligible).
    • Surgical margins that cannot be microscopically assessed or are positive at pathologic evaluation. (If surgical margins are rendered free of disease by re- excision, the patient is eligible).
    • Treatment plan that includes regional nodal irradiation.
    • Any treatment with radiation therapy, chemotherapy, biotherapy, and/or endocrine therapy administered for the currently diagnosed breast cancer prior to study entry. (Short course endocrine therapy of less than 6 weeks duration is acceptable post core biopsy pre surgery if the Oncotype DX Recurrence Score is assessed on the biopsy core and is less than or equal to 18).
    • History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to study entry.
    • Current therapy with any endocrine therapy such as raloxifene (Evista®), tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or breast cancer prevention. (Short course endocrine therapy of < 6 weeks duration is acceptable post core biopsy pre surgery if the Oncotype DX Recurrence Score is assessed on the biopsy core and is less than or equal to 18).
    • Patients intending to continue on oral, transdermal, or subdermal estrogen replacement (including all estrogen only and estrogen-progesterone formulas) are not eligible.
    • Patients that discontinue oral, transdermal, or subdermal estrogen replacement prior to registration are eligible.
    • Prior breast or thoracic RT for any condition.
    • Active collagen vascular disease, specifically dermatomyositis with a CPK level above normal or with an active skin rash, systemic lupus erythematosis, or scleroderma.
    • Pregnancy or lactation at the time of study entry or intention to become pregnant during treatment.
      • Note: Pregnancy testing according to institutional standards for women of childbearing potential must be performed within 2 weeks prior to study entry.
    • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of study therapy or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
    • Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with interpretation of study results.
    • Use of any investigational product within 30 days prior to study entry.

    Eligibility last updated 9/20/21. Questions regarding updates should be directed to the study team contact.

    Other, Drug
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic Health System — Mankato, MN

    NRG-BR007, A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    Timothy Kozelsky
    All
    50 years to 70 years old
    Phase 3
    This study is NOT accepting healthy volunteers
    2021-305950-P01-ALCL
    21-009845
    Show full eligibility criteria
    Hide eligibility criteria

    Inclusion Criteria:

    • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the U.S., authorization permitting release of personal health information.
    • The patient must have an ECOG performance status of 0 or 1.
    • The patient must have undergone a lumpectomy and the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS with no ink on tumor as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional excisions may be performed to obtain clear margins. (Patients with margins positive for LCIS are eligible without additional resection).
    • The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination.
    • Patient must have undergone axillary staging (sentinel node biopsy and/or axillary node dissection).
    • The following staging criteria must be met postoperatively according to AJCC 8th edition criteria:
      • By pathologic evaluation, primary tumor must be pT1 (less than or equal to 2 cm);
      • By pathologic evaluation, ipsilateral nodes must be pN0. (Patients with pathologic staging of pN0(i+) or pN0(mol+) are NOT eligible);
      • Oncotype DX Recurrence Score of less than or equal to 18 on diagnostic core biopsy or resected specimen;
        • ** For patients with a T1a tumor (less than or equal to 0.5 cm in size) who do not already have an Oncotype DX Recurrence Score at study entry, a specimen (unstained blocks or slides) must be sent to the Genomic Health centralized laboratory.
      • The tumor must have been determined to be ER and/or PgR positive assessed by current ASCO/CAP Guideline Recommendations for hormone receptor testing. Patients with greater than or equal to 1% ER or PgR staining by IHC are considered positive;
      • The tumor must have been determined to be HER2-negative by current ASCO/CAP guidelines.
    • Patients may be premenopausal or postmenopausal at the time of study entry. For study purposes, postmenopausal is defined as: age 56 or older with no spontaneous menses for at least 12 months prior to study entry; or a documented hysterectomy; or age 55 or younger with no spontaneous menses for at least 12 months prior to study entry (e.g., spontaneous or secondary to hysterectomy) and with a documented estradiol level in the postmenopausal range according to local institutional/laboratory standard; or documented bilateral oophorectomy.
    • The interval between the last surgery for breast cancer (including re-excision of margins) and study entry must be no more than 70 days.
    • The patient must have recovered from surgery with the incision completely healed and no signs of infection.
    • Bilateral mammogram or MRI within 6 months prior to study entry. HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
    • Patients must be intending to take endocrine therapy for a minimum 5 years duration (tamoxifen or aromatase inhibitor). The specific regimen of endocrine therapy is at the treating physician's discretion.


    Exclusion Criteria:

    • Definitive clinical or radiologic evidence of metastatic disease. -pT2
      •pT4 tumors including inflammatory breast cancer.
    • Pathologic staging of pN0(i+) or pN0(mol+), pN1, pN2, or pN3 disease.
    • Patient had a mastectomy.
    • Palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor.
    • Suspicious microcalcifications, densities, or palpable abnormalities (in the ipsilateral or contralateral breast) unless biopsied and found to be benign.
    • Non-epithelial breast malignancies such as sarcoma or lymphoma.
    • Proven multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or separated by 4 or more centimeters. (Patients with multifocal carcinoma are eligible).
    • Paget's disease of the nipple.
    • Any history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated or not treated. (Patients with synchronous or previous ipsilateral LCIS are eligible).
    • Synchronous or previous contralateral invasive breast cancer or DCIS. (Patients with synchronous and/or previous contralateral LCIS are eligible).
    • Surgical margins that cannot be microscopically assessed or are positive at pathologic evaluation. (If surgical margins are rendered free of disease by re- excision, the patient is eligible).
    • Treatment plan that includes regional nodal irradiation.
    • Any treatment with radiation therapy, chemotherapy, biotherapy, and/or endocrine therapy administered for the currently diagnosed breast cancer prior to study entry. (Short course endocrine therapy of less than 6 weeks duration is acceptable post core biopsy pre surgery if the Oncotype DX Recurrence Score is assessed on the biopsy core and is less than or equal to 18).
    • History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to study entry.
    • Current therapy with any endocrine therapy such as raloxifene (Evista®), tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or breast cancer prevention. (Short course endocrine therapy of < 6 weeks duration is acceptable post core biopsy pre surgery if the Oncotype DX Recurrence Score is assessed on the biopsy core and is less than or equal to 18).
    • Patients intending to continue on oral, transdermal, or subdermal estrogen replacement (including all estrogen only and estrogen-progesterone formulas) are not eligible.
    • Patients that discontinue oral, transdermal, or subdermal estrogen replacement prior to registration are eligible.
    • Prior breast or thoracic RT for any condition.
    • Active collagen vascular disease, specifically dermatomyositis with a CPK level above normal or with an active skin rash, systemic lupus erythematosis, or scleroderma.
    • Pregnancy or lactation at the time of study entry or intention to become pregnant during treatment.
      • Note: Pregnancy testing according to institutional standards for women of childbearing potential must be performed within 2 weeks prior to study entry.
    • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of study therapy or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
    • Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with interpretation of study results.
    • Use of any investigational product within 30 days prior to study entry.

    Eligibility last updated 9/20/21. Questions regarding updates should be directed to the study team contact.

    Other, Drug
    I'm interested
    Share via email
    Show 1 location
    Hide all locations

    Location Contacts
    Mayo Clinic Health System — Albert Lea, MN